For investors, patients, and industry observers tracking the biotechnology sector, the question of whether Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) remains an independent entity is a common one. Given the rapid shifts in the pharmaceutical landscape, understanding the current status of this company requires looking at its transition from an independent clinical-stage firm to its integration into a larger global organization.
Table of contents
The Evolution of Longboard Pharmaceuticals
Longboard Pharmaceuticals launched as an independent company in October 2020, spinning out from Arena Pharmaceuticals. The company was built on a foundation of two decades of experience in discovering and optimizing GPCR (G-protein-coupled receptor) therapies. Throughout its tenure as an independent, publicly traded entity, Longboard focused heavily on developing innovative medicines for neurological conditions, maintaining a robust clinical development pipeline.
The Acquisition by Lundbeck
The most significant milestone in the company’s recent history is its acquisition by the global pharmaceutical giant H. Lundbeck A/S (Lundbeck). In a strategic move designed to significantly enhance Lundbeck’s neuroscience pipeline, the boards of directors of both companies unanimously approved a definitive agreement for Lundbeck to acquire Longboard Pharmaceuticals.
Key details regarding the transaction include:
- Strategic Intent: Lundbeck sought to bolster its portfolio with Longboard’s promising assets in the neuroscience space.
- Timeline: The transaction was officially expected to close in the fourth quarter of 2024, subject to customary closing conditions, including the tender of a majority of Longboard’s outstanding voting shares and necessary regulatory clearances.
Current Status: Is it Still “In Business”?
As of July 31, 2026, Longboard Pharmaceuticals no longer operates as an independent, publicly traded company. Following the successful completion of the acquisition in late 2024, the company was integrated into the Lundbeck organization.
While the brand and the clinical programs initiated by Longboard continue to exist, they are now managed under the corporate umbrella of Lundbeck. Investors who previously tracked the LBPH ticker on the Nasdaq will find that the company is no longer listed as a standalone entity. Instead, the research and development efforts formerly under the Longboard banner are now part of Lundbeck’s broader mission to treat brain diseases.
Summary for Stakeholders
If you are looking for information regarding Longboard’s legacy operations, clinical trials, or financial history, you should now direct your inquiries to Lundbeck. The acquisition was a pivotal moment that transitioned Longboard from a small-cap clinical-stage firm into a key component of a major international pharmaceutical company.
Disclaimer: This article is for informational purposes based on historical data regarding the acquisition of Longboard Pharmaceuticals by Lundbeck. It does not constitute financial advice or investment recommendations. Always consult official corporate filings or investor relations resources for the most current information regarding company acquisitions and status.
